Role of inflammatory cytokines in depression: Focus on interleukin-1β
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
According to the World Health Organization, major depression will become the leading cause of disability worldwide by the year 2030. Despite extensive research into the mechanisms underlying this disease, the rate, prevalence and disease burden has been on the rise, particularly in the industrialized world. Epidemiological studies have shown biological and biochemical differences in disease characteristics and treatment responses in different age groups. Notable differences have been observed in the clinical presentation, co-prevalence with other diseases, interaction with the immune system and even in the outcome. Thus, there is an increased interest in characterizing these differences, particularly in terms of contribution of different factors, including age, cytokines and immunotherapy. Research into the possible mechanisms of these interactions may reveal novel opportunities for future pharmacotherapy. The aim of the present review is to document recent literature regarding the impact of inflammatory mechanisms on the pathophysiology of the depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386 · cited 1×
“Major depression is set to become the leading cause of disability worldwide by the year 2030 (1).”
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Biological basis of the behavior of sick animals
Hart, B. L. (1988) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(88)80004-6 · Cited by 2,223 · cited 2×
“Sickness behavior, first reported by Hart (12), was characterized by hyperthermia, lethargy, sleep and appetite disturbances, and reduced grooming, which arose as a consequence of an infectious stimulus.”
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?
Yudkin, J. S., Kumari, M., Humphries, S. E., & Mohamed-Ali, V. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00463-3 · Cited by 1,775
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282
The Pathophysiologic Roles of Interleukin-6 in Human Disease
Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., & Chrousos, G. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00009 · Cited by 1,146
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120 · cited 1×
“In another setting, a pretreatment with SSRI, paroxetine successfully prevented the onset of depressive symptoms in a significant number of patients undergoing high-dose IFN-α therapy for malignant melanoma as compared to those who were not pre-treated with the same antidepressant (66).”
Liu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
The macrophage theory of depression
Smith, R. S. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90272-z · Cited by 931 · cited 1×
“Since Smith (9) presented a study of the implications of cytokines in depressive-like behavior, establishing the etiology and pathogenesis of depression has become a point of research.”
Positive Psychology: An Introduction
Seligman, M. E. P., & Csikszentmihalyi, M. (2014) · Flow and the Foundations of Positive Psychology · doi:10.1007/978-94-017-9088-8_18 · Cited by 911
Cited by
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review
Cortes Rivera, M., Mastronardi, C., Silva-Aldana, C., Arcos-Burgos, M., & Lidbury, B. (2019) · Diagnostics · doi:10.3390/diagnostics9030091 · Cited by 313
Selected biomarkers of depression: what are the effects of cytokines and inflammation
Harsanyi, S., Kupcova, I., Danisovic, L., & Klein, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010578 · Cited by 299
“However, their peripheral levels are also studied in association with antidepressant treatment [15,16].”
BackgroundAlli, S. R., Gorbovskaya, I., Liu, J. C. W., Kolla, N. J., Brown, L., & Müller, D. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094494 · Cited by 202
“For example, depression is associated with the release of C-reactive protein (CRP) and cytokines such as IL-1, IL-2, IL-6, IFN-γ, and IL-1β [19].”
BackgroundSerum Interferon-Gamma Level Is Associated with Drug-Naïve Major Depressive Disorder
Daria, S., Proma, M. A., Shahriar, M., Islam, S. M. A., Bhuiyan, M. A., & Islam, M. R. (2020) · SAGE Open Medicine · doi:10.1177/2050312120974169 · Cited by 46
Mello, B. S. F., Chaves Filho, A. J. M., Custódio, C. S., Cordeiro, R. C., Miyajima, F., de Sousa, F. C. F., Vasconcelos, S. M. M., de Lucena, D. F., & Macedo, D. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.04.009 · Cited by 45
Maneenet, J., Monthakantirat, O., Daodee, S., Boonyarat, C., Chotritthirong, Y., Kwankhao, P., Pitiporn, S., Awale, S., & Chulikhit, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14070659 · Cited by 10
Metadata
- Authors
- Farooq, R. K., Asghar, K., Kanwal, S., & Zulqernain, A.
- Venue
- Biomedical Reports
- Publisher
- Spandidos Publications
- Published
- 2016-11-10
- Volume
- 6
- Issue
- 1
- Pages
- 15-20
- ISSN
- 2049-9434 (ISSN-L)
- 2049-9442
- OpenAlex
- W2555082051
- Cited by
- 153
- References
- 31
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.